SYD1875

Byondis B.V. · Phase 1 active Small molecule

At a glance

Generic name	SYD1875
Sponsor	Byondis B.V.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SYD1875 CI brief — competitive landscape report
SYD1875 updates RSS · CI watch RSS
Byondis B.V. portfolio CI